Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

QuidelOrtho launches certified analyzer program

October 2025—QuidelOrtho Corp. has launched a certified analyzer program designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. The program is tailored for clinics, physician office labs, and small hospitals with fewer than 100 beds. Each analyzer in the program undergoes a robust, multipoint certification process at QuidelOrtho’s Rochester, NY, facility. It includes more than 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. The program features certified Vitros XT 7600 and 5600 integrated systems and the Vitros 3600 immunodiagnostic system. A 12-month warranty on service and support is included.

StatLab launches PiSmart S1 slide printer

October 2025—StatLab Medical Products has launched the PiSmart S1 single hopper slide printer. The PiSmart S1 features an intuitive touchscreen interface and a compact footprint that supports on-demand printing. Four years of service is included with the use of StatLab-validated slides, which will soon be manufactured at the company’s Arlington, Tex., facility. This integrated approach—pairing printers with precision-manufactured, validated KT premium slides—creates a complete solution built for accuracy and reliability, according to a press release from StatLab.

Idylla CDx MSI test gets FDA premarket approval

October 2025—Biocartis’ Idylla CDx MSI test, developed in partnership with Bristol Myers Squibb, has received FDA premarket approval. The test aids in identifying eligible microsatellite instability-high colorectal cancer patients who may benefit from treatment with Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), as established in the CheckMate 8HW trial.

Bio-Rad launches Unity Next Peer QC in Asia-Pacific region

October 2025—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software throughout the Asia-Pacific region. The software is designed to help troubleshoot quality control errors and increase confidence in patient testing results. It offers on-demand access to peer reporting and quality control data and provides data visualization and report generation for compliance management. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.

Randox expands its operations in West Virginia

October 2025—Randox Laboratories plans to expand its facility in Jefferson County, W. Va., from a 48-person sales and distribution operation to a full-scale production laboratory. The company says the expansion will further increase its annual production of 4.1 billion tests and significantly enhance its capacity to serve customers worldwide, from hospitals, laboratories, and coroners’ offices to food safety testing facilities. The project will create opportunities for local suppliers and service providers. Once complete, the upgraded facility in Kearneysville will produce next-generation diagnostic products and equipment.

Scopio receives fourth FDA clearance

October 2025—Scopio Labs received FDA clearance to include decision support system features for its X100 and X100HT platforms and Peripheral Blood Smear Application. The upgraded solution provides AI-driven analysis and grading for 23 distinct RBC morphology parameters and for the presence of platelet clumps across the clinically relevant areas of the sample, from the monolayer to the feathered edge.

New book on interpreting coagulation test results

October 2025—Knowledge of laboratory tests that most effectively work up a patient presenting with bleeding or clotting manifestations is crucial to develop a sound and timely action plan for the benefit of the patient. It is important for medical professionals to know which tests best evaluate the causes of hemostasis disorders and what common clinical scenarios can significantly interfere with accurate test results, such as the impact of anticoagulant agents on routine and special coagulation assay results.

MeMed completes development of BV Flex test

October 2025—MeMed has completed its multiyear development of MeMed BV Flex, a next-generation test designed to expand the reach of MeMed BV into decentralized, CLIA-waived settings. The test enables differentiation between bacterial and viral infections in 15 minutes using capillary blood from a finger prick.

Agilent MMR IHC panel approved as a CDx for colorectal cancer

October 2025—Agilent Technologies MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic test for colorectal cancer. The test aids in identifying mismatch repair deficient colorectal cancer patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo (nivolumab) or Opdivo in combination with Yervoy (ipilimumab). It was developed and validated to detect the loss of function of any of the four MMR proteins in formalin-fixed, paraffin-embedded colorectal cancer tissue.

OGT, Qiagen partner to offer sample-to-report workflow

October 2025—OGT and Qiagen Digital Insights are partnering to expand OGT’s bioinformatics capabilities by integrating Qiagen’s tertiary analysis solution, QCI Interpret, with OGT’s SureSeq next-generation sequencing panels. QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq NGS panel users will have access to streamlined genomic insights and efficient, scalable reporting from sample to result.

MARKETPLACE

TRENDING